Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
5/29/2026, 12:00:00 AM
The CARES Phase III clinical program for anselamimab did not meet its primary endpoint on 2026-05-29, but a prespecified subgroup analysis showed a clinically meaningful benefit for patients with kappa light chain amyloidosis; low market impact (>=1%) expected due to mixed clinical results.
Korean Translation
2026년 5월 29일 안셀라맙의 CARES 3상 임상 결과가 발표됨. 1차 평가변수 미충족에도 불구하고 특정 하위 그룹에서의 유효성 확인으로 1% 이상의 주가 영향이 예상됨.
Related Recent Events
Abbott Laboratories (ABT) · Earnings Release
Abbott's Q2 2026 earnings release is scheduled for July 16, 2026. Analysts forecast EPS of $1.28. Medium importance estimated as earnings typically drive >5% price movement expected.
7/16/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Quarterly cash dividend of $1.25 per share has an ex-dividend date of June 12, 2026. The dividend is scheduled to be paid on June 26, 2026.
6/12/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
New Phase 3 data for the pipeline drug CagriSema to be presented at the American Diabetes Association (ADA) Scientific Sessions on June 7, 2026, with a low price impact scheduled.
6/7/2026, 12:00:00 AM
Lululemon Athletica Inc (LULU) · Earnings Release
Lululemon Athletica is scheduled to release its financial results for the first quarter of fiscal 2026 on June 4, 2026, after the market closes. High importance is estimated as earnings releases typically result in significant price volatility. scheduled
6/4/2026, 12:00:00 AM
Life Time Group Holdings Inc (LTH) · Other
RBC Capital analysts forecast a price target of $43.00 for Life Time Group Holdings on June 2, 2026; target increases typically suggest a low positive impact, forecasted.
6/2/2026, 12:00:00 AM
Astrazeneca PLC (AZN) · Other
Positive results from the EMERALD-3 Phase III trial were presented at the ASCO 2026 meeting on 2026-06-01, showing that Imfinzi and Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in patients with unresectable liver cancer; high market impact (>=10%) expected due to significant clinical efficacy.
6/1/2026, 12:00:00 AM